Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018

Publisher Name :
Date: 31-Oct-2018
No. of pages: 302
Inquire Before Buying

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 22, 10, 41, 2 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 11 and 2 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018

Table of Contents
Table of Contents 2
Introduction 5
Human Papillomavirus (HPV) Associated Cancer - Overview 6
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development 7
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 19
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 28
Human Papillomavirus (HPV) Associated Cancer - Drug Profiles 52
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 275
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products 278
Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 279
Appendix 291

List of Tables
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abivax SA, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antiva Biosciences Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cue Biopharma Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Denceptor Therapeutics Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corp, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Hookipa Biotech AG, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunomic Therapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by IMV Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Juno Therapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune LLC, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Merck & Co Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Merck KGaA, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by NeoImmuneTech Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oxford Vacmedix UK Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Pathovax LLC, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by PDS Biotechnology Corp, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Rottapharm Biotech Srl, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shuttle Pharmaceuticals Inc, H2 2018

List of Figures
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • Global Cancer Immunomodulator Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
  • Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
  • Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 125
    According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period. Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
  • Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 112
    This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
  • Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Gene Therapy market: According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
  • T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 85
    CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
  • Global Kaposi Sarcoma Market Status and Outlook 2023-2028
    Published: 22-Dec-2023        Price: US 3160 Onwards        Pages: 107
    Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
  • Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Cancer Immunomodulator market: According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs